• Implications of multiprobiotics and fructooligosaccharides on functional bowel pathology in infants
To content

Implications of multiprobiotics and fructooligosaccharides on functional bowel pathology in infants

SOVREMENNAYA PEDIATRIYA.2014.4(60):133-139;doi 10.15574/SP.2014.60.133

Implications of multiprobiotics and fructooligosaccharides on functional bowel pathology in infants

Marushko R. V. 
SI «Institute of Pediatrics, Obstetrics and Gynecology of National Academy of Medical Science of Ukraine », Kiev

Aim of this study was to evaluate the efficacy of the preparation called «Lactiale Maljuk» in the treatment of functional bowel diseases in infants associated with intestine dysbiosis.

Materials and Methods. We examined 104 children aged 6 to 18 months, of which 55 children with functional constipation (FC) and 49 children with function al diarrhea (FD). Underwent clinical and laboratory investigations, including bacteriological and immunological (TNF-a  in blood serum, SIgA in fesus samples). Studied the clinical efficacy of the preparation «Lactiale Maljuk» — a combination of the multi probiotic and fructooligosaccharides in FC and FD in infants.

Results. Revealed significant disorders in the status of intestinal microbial flora, the main representatives of indigenous microflora (Bifidobacterium, Lactobacillus), an increase in the expression of TNF-a  in serum and decrease the concentration of SIgA in fesus samples in infants with FC and FD. Use the combination of multiprobiotics which contains symbiotic complex of probiotic bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus ther mophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus) and fructooligosaccharides (prebiotic) in a preparation «Lactiale Maljuk» has a pronounced positive effect on the clinical course of functional constipation and functional diarrhea, contributes to the nor malization and restoration of intestinal microbial flora, immune system parameters in infants with this pathology.

Conclusions. The results of the study of the efficiency in using the preparation «Laktiale Maljuk» allows us to recommend this preparation for use in infants with functional constipation and functional diarrhea in prevention, treatment and rehabilitation of this pathology.

Key words: infants, functional bowel diseases, immune system, intestinal microflora.

REFERENCES 
1. Андреева ИВ. 2011. Когда следует назначать пробиотики? Клин микробиол и антимикробная химиотерапия. 13;3: 279—282.

2. Ардатская МД. 2011. Пре- и пробиотики в коррекции микроэкологических нарушений кишечника. Фарматека. 12: 62—68.

3. Белоусова ОЮ. 2011. Дисбактериоз кишечника как фактор риска развития хронических заболеваний кишечника у детей. Здоровье ребенка. 1: 73—75.

4. Про затвердження уніфікованих клінічних протоколів медичної допомоги дітям із захворюваннями органів травлення. Наказ МОЗ України від 29.01.2013 № 59. http://www.moz.gov.ua.

5. Щеплягина ЛА, Круглова ИВ, Перцева ВА. 2011. Секреторный иммунитет кишечника у детей раннего возраста. Consilium Medicum. Педиатрия. 3: 9—11.

6. Яковенко ЭП, Лаврентьева СА, Яковенко АВ. 2012. Инновационные пробиотики — ключ к управлению функциями нормальной кишечной микрофлоры. Лечащий Врач. 7: 30—32.

7. Albenberg LG, Lewis JD, Wu GD. 2012. Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol. 28;4: 314—320.

8. Karlsson F, Tremaroli V, Nielsen J, Backhed F. 2013. Assessing the human gut microbiota in metabolic diseases. Diabetes. 62;10: 3341—3349.

9. Hoa N, Prasadb V. 2013. Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Ann Gastroenterol. 26;3: 277—278.

10. Kelly D, Mulder IE. 2012. Microbiome and immunological interactions. Nutr Rev. 70;Suppl 1: 18—30.

11. Valles Y, Gosalbes MJ, de Vries LE et al. 2012. Metagenomics and development of the gut microbiota in infants. Clin Microbiol Infect. 18;Suppl 4: 21—26.

12. Timmerman HM, Koning CJ, Mulder L et al. 2004. Monostrain, multistrain and multispecies probiotics— A comparison of functionality and efficacy. Int J Food Microbiol. 96;3: 219—233.

13. Neu J. 2014. The developing intestinal microbiome: probiotics and prebiotics. World Rev Nutr Diet. 110: 167—176.

14. Ohman L, Simren M. 2010. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 7;3: 163—173.

15. Petschow B, Dore J, Hibberd P et al. 2013. Probiotics, prebiotics, and the host microbiome: the science of translation. Ann N Y Acad Sci. 1306: 1—17.

16. Quigley EM. 2011. Microflora modulation of motility. J Neurogastroenterol Motil. 17;2: 140—147.

17. Drossman DA, Corazziari E, Delvaux M et al. 2006. ROME III: The Functional Gastrointestinal Disorders. Yale University Section of Digestive Disease: Degnon Associates. 3rd ed: 1048.

18. Koning CJ, Jonkers D, Smidt H et al. 2010. The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics. Br J Nutr. 103;10: 1452—1460.

19. Tremaroli V, Backhed F. 2012. Functional interactions between the gut microbiota and host metabolism. Nature. 489;7415: 242—249.

20. Walker WA. 2013. Initial intestinal colonization in the human infant and immune homeostasis. Ann Nutr Metab. 63; Suppl 2: 8—15.

21. Young VВ. 2012. The intestinal microbiota in health and disease. Curr Opin Gastroenterol. 28: 63—69.